NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
2
Clinical Trials (2)
Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
Started Aug 2022
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Started May 2022
Loss of Exclusivity
LOE Date
Mar 15, 2044
219 months away
Patent Expiry
Mar 15, 2044
Exclusivity Expiry
Jul 31, 2030